Basic information
Biomarker: Plasminogen activator inhibitor-type 2 (PAI-2)
Histology type: endometrial carcinoma
Stage: IC
Cohort characteristics
Country: Ireland
Region: Dublin
Followed up time :
Subgroup 1 name : postmenopausal malignant endometrium patients
Subgroup 1 number: 21
Subgroup 2 name: normal endometrium postmenopausal patients
Subgroup 2 number: 21
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 42 | postmenopausal patients malignant endometrium | 21 | normal endometrium postmenopausal patients | 21 |
Sample information
Conclusion: PAI-2 may be useful as a prognostic marker in endometrial cancer.Levels of endometrial PAI-2 were higher in stages IC or greater compared to those in stages IA and 1B cancers.
Sample type : tissue
Sample method: Enzyme-linked immunoassays
Expression pattern : high((range, 1.6-27.3; median, 4.9 ng/mg protein))
Disease information
Related information
Funtion Uniprot: Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
UniProt ID: P00749
UniProt Link: https://www.uniprot.org/uniprotkb/P00749/entry
Biological function from UniProt: Blood coagulation, Fibrinolysis, Hemostasis, Plasminogen activation
Molecular function from UniProt:
Tissue specificity from UniProt: Expressed in the prostate gland and prostate cancers.
Subcellular UniProt: #Secreted
Alternative name from UniProt:
Catalytic activity: Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.
Gene name from HGNC: PLAU (UPA, URK)
HPA link: https://www.proteinatlas.org/ENSG00000122861-PLAU
Tissue specificity RNA from HPA: Tissue enhanced (kidney, urinary bladder)
Tissue expression from HPA: Cytoplasmic and membranous expression in several tissues.
Subcellular summary HPA Located in Golgi apparatus, Vesicles (Single cell variability)
Cancer prognostic summary HPA Prognostic marker in pancreatic cancer (unfavorable), head and neck cancer (unfavorable), endometrial cancer (favorable), renal cancer (unfavorable) and lung cancer (unfavorable)
Pathology link: https://www.proteinatlas.org/ENSG00000122861-PLAU/tissue
Pathology endo: https://www.proteinatlas.org/ENSG00000122861-PLAU/tissue/duodenum
Note2: BLEEDING DISORDER, PLATELET-TYPE, 5; BDPLT5 FACTOR V QUEBEC
OMIM: 191840;601709;
OMIM link2: https://www.omim.org/entry/191840
Phenotype: QUEBEC PLATELET DISORDER; QPD
HGNC ID: HGNC:9052
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9052
